With a median follow up of 3.8 years, the data demonstrated superiority of early TAVR, with 26.8% of the 455 patients in the TAVR arm experiencing death, stroke or unplanned cardiovascular ...

During the fourth quarter, TAVR procedures generated $1.04 billion in sales, growing 6% year over year, or 5% in constant currency. That beat forecasts for $1.01 billion, according to FactSet.

Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for treatment of severe asymptomatic aortic stenosis, the first in this patient population ...

Edwards Lifesciences (EW) announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis ...

Last fall, at the TCT conference in Washington, D.C., a randomized study from Edwards of patients with aortic stenosis showed that receiving a TAVR implant before cardiac symptoms take a turn ...

Procedures were scheduled about 32 days after symptoms developed, on average, and the vast majority underwent a TAVR procedure. There were also no apparent differences in procedural complications ...